Biocon: Japan Biosimilar Glargine Nod To Open Other Doors
This article was originally published in PharmAsia News
Executive Summary
India's largest biopharmaceutical company, Biocon, has reported quarterly net profit rocketed nearly 80% thanks to exceptional income, and says Japan's regulatory nod for its insulin glargine should help “fast-track” approvals of the biosimilar in both emerging markets and advanced economies.